https://www.avient.com/sites/default/files/2024-10/Terms%26Conditions - Brazil English %26 Portuguese.pdf
Buyer must give Seller
written notice of the existence of each claim
involving Product (whether based in
contract, breach of warranty, negligence,
strict liability, other tort or otherwise)
within the earlier of thirty (30) days after
receipt of the quantity of Product forming
the basis for the claim or applicable shelf-
-‐life expiration, if any.
No modification or addition
to this contract shall occur by the
acknowledgment or acceptance by Seller of
a purchase order, acknowledgment, release
or other form submitted by Buyer
containing additional or different terms or
conditions, and Seller hereby gives Buyer
notice of the rejection of such additional
terms and conditions.
https://www.avient.com/sites/default/files/resources/POL%2520IR%2520Presentation%2520-%2520BOAML%2520Basic%2520Materials%2520Conference%2520w%2520non-GAAP%252012%252011%25202014.pdf
You are
advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and
Exchange Commission.
https://www.avient.com/sites/default/files/resources/POL%2520IR%2520Presentation%2520Jefferies%2520Conf%2520w%2520Non%2520GAAP%252008%252012%25202014.pdf
You are
advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and
Exchange Commission.
https://www.avient.com/sites/default/files/resources/POL%2520IR%2520Presentation%2520Credit%2520Suisse%2520w%2520non%2520GAAP%25206%252025%25202014.pdf
You are
advised to consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and
Exchange Commission.
https://www.avient.com/sites/default/files/resources/POL%2520IR%2520Presentation%2520GS%2520w%2520non%2520GAAP%25205_21_14.pdf
You are advised to
consult any further disclosures we make on related subjects in our reports on Form 10-Q, 8-K and 10-K that we provide to the Securities and Exchange Commission.
https://www.avient.com/sites/default/files/2022-06/MEVOPUR Bio-based Solutions Application Bulletin_CN %281%29.pdf
埃万特的产品不为以下目的或用途而设计，也不会宣传或预期用于以下目的或用途：
(a) 被美国食品药品监督管理局（FDA）或国际标准化组织（ISO）归类为“植入”类器械的医疗器械；或美国药典（USP）或ISO标准定义的“永久”使用器械；或
(b) 经修订的欧盟指令90/385/EEC中定义的有源植入式医疗器械；或者
(c) 经修订的欧盟指令93/42/EEC中定义的“长期”使用的医疗器械。
https://www.avient.com/sites/default/files/2022-08/MEVOPUR Special Effect Colors Application Bulletin_CN.pdf
埃万特的产品不为以下目的或用途而设计，也不会宣传或预期用于以下目的或用途：
(a) 被美国食品药品监督管理局（FDA）或国际标准化组织（ISO）归类为“植入”类器械的医疗器械；或美国药典（USP）或ISO标准定义的“永久”使用器械；或
(b) 经修订的欧盟指令90/385/EEC中定义的有源植入式医疗器械；或者
(c) 经修订的欧盟指令93/42/EEC中定义的“长期”使用的医疗器械。
https://www.avient.com/sites/default/files/2021-09/mevopur-colors-for-ophthalmic-closures-application-bulletin-cn.pdf
埃万特的产品不为以下目的或用途而设计，也不会宣传或预期用于以下目的或用途：
(a) 被美国食品药品监督管理局（FDA）或国际标准化组织（ISO）归类为“植入”类器械的医疗器械；或美国药典（USP）或ISO标准定义的“永久”使用器械；或
(b) 经修订的欧盟指令90/385/EEC中定义的有源植入式医疗器械；或者
(c) 经修订的欧盟指令93/42/EEC中定义的“长期”使用的医疗器械。
https://www.avient.com/sites/default/files/2025-04/Supplier Code of Conduct FV_Germ.pdf
B.
https://www.avient.com/sites/default/files/2021-03/avient-antitrust-2021-update-sv-a4.pdf
Undvik all form av taktik som skulle kunna
tolkas som menad att inom vilken som helst
verksamhetsledd verksamhet slå ut samtliga
eller en betydande andel av Avients konkurrenter
från marknaden eller som ett försök att på ett
konkurrensbegränsande sätt utplåna en viss
konkurrent eller kontrollera priser.
b.